Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by StockNews.com to “Strong-Buy” Rating

Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Friday.

A number of other research analysts have also recently issued reports on CPRX. Truist Financial boosted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Finally, Stephens began coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock traded down $0.21 during trading on Friday, hitting $21.31. 564,099 shares of the company were exchanged, compared to its average volume of 713,299. The firm has a market capitalization of $2.54 billion, a P/E ratio of 18.06, a price-to-earnings-growth ratio of 3.35 and a beta of 0.75. The firm’s fifty day moving average price is $21.80 and its 200 day moving average price is $19.73. Catalyst Pharmaceuticals has a 1-year low of $13.12 and a 1-year high of $24.27.

Insider Buying and Selling

In related news, insider Gary Ingenito sold 12,000 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the transaction, the insider now owns 51,391 shares in the company, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the transaction, the insider now directly owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 79,500 shares of company stock valued at $1,754,140. Company insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Arizona State Retirement System lifted its stake in Catalyst Pharmaceuticals by 2.2% in the second quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock valued at $461,000 after acquiring an additional 654 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 681 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Catalyst Pharmaceuticals by 7.5% during the 2nd quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 773 shares during the period. Sei Investments Co. increased its holdings in shares of Catalyst Pharmaceuticals by 1.3% during the 2nd quarter. Sei Investments Co. now owns 84,458 shares of the biopharmaceutical company’s stock worth $1,308,000 after acquiring an additional 1,098 shares during the last quarter. Finally, Assetmark Inc. raised its stake in Catalyst Pharmaceuticals by 2.4% in the 3rd quarter. Assetmark Inc. now owns 72,245 shares of the biopharmaceutical company’s stock valued at $1,436,000 after acquiring an additional 1,704 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.